1. CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy
- Author
-
Stanislav Keranov, Leili Jafari, Saskia Haen, Julia Vietheer, Steffen Kriechbaum, Oliver Dörr, Christoph Liebetrau, Christian Troidl, Wiebke Rutsatz, Andreas Rieth, Christian W. Hamm, Holger Nef, Andreas Rolf, and Till Keller
- Subjects
fibrosis ,MRI ,myocardial remodeling ,RVEF ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract The aim of this study was to evaluate the cartilage intermediate layer protein 1 (CILP1) as a biomarker of right ventricular dysfunction in patients with ischemic cardiomyopathy (ICM). CILP1 plasma concentrations were measured in 98 patients with ICM and 30 controls without any cardiac abnormalities. All participants underwent cardiac magnetic resonance imaging. Median CILP1 concentrations were higher in ICM than in controls. In the tertile analysis, low right ventricular ejection fraction (RVEF) and high right ventricular end‐systolic volume index and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) were associated with higher CILP1 levels in ICM. However, there were no associations between CILP1 concentrations and left ventricular (LV) parameters in this group. In receiver‐operating characteristic (ROC) analysis CILP1 was a good predictor of RVEF
- Published
- 2022
- Full Text
- View/download PDF